Cytarabine - Evaluation of the effects on reproduction, recommendation for classification
Health Council of the Netherlands
Record ID 32015001016
English
Authors' recommendations:
In the present report, the Health Council of the Netherlands reviewed cytarabine. Cytarabine is a pyrimidine nucleoside analogue that inhibits the synthesis of DNA. It is used as an antineoplastic drug for the treatment of leukaemia, especially acute non-lymphoblastic leukaemia. This report is part of a series, in which the Health Council evaluates the effects of substances on reproduction, at the request of the Minister of Social Affairs and Employment. It mainly concerns substances to which man can be exposed occupationally. The Subcommittee on the Classification of Reproduction Toxic Substances of the Dutch Expert Committee on Occupational Safety (DECOS) of the Health Council, hereafter called the Committee, evaluates the effects on the male and female fertility and on the development of the progeny. Moreover, the Committee considers the
effects of a substance on lactation and on the progeny via lactation.
The Committee recommends classification according to regulation (EC) 1272/2008 of the European Union. For cytarabine, these recommendations are:
• for effects on fertility, the Committee recommends not classifying cytarabine due to a lack of appropriate data
• for effects on development, the Committee recommends classifying cytarabine in category 1B (presumed human reproductive toxicant) and labelling with H360D (may damage the unborn child)
• for effects on or via lactation, the Committee recommends not labelling cytarabine due to a lack of appropriate data.
Details
Project Status:
Completed
Year Published:
2015
URL for published report:
http://www.gezondheidsraad.nl/sites/default/files/201518_cytarabine_1.pdf
English language abstract:
An English language summary is available
Publication Type:
Not Assigned
Country:
Netherlands
MeSH Terms
- Antineoplastic Agents
- Reproduction
Contact
Organisation Name:
Health Council of the Netherlands Gezondheidsraad
Contact Address:
Postbus 16052, 2500 BB Den Haag, The Netherlands. Tel: +31 70 340 7520;Fax: +31 70 340 7523
Contact Name:
info@gr.nl
Contact Email:
info@gr.nl
Copyright:
Health Council of the Netherlands
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.